title: [Biotherapeutic efficacy of adoptive transfer of CD3AK cells in combination with cyclophosphamide and kappa-selenocarrageenan in P 388 leukemic mice].
abstract: OBJECTIVE
  To study the antileukemia efficacy of a combination of adoptive transfer of CD3AK cells, cyclophosphamide (CTX), and kappa-selenocarrageenan (KSC) in P 388 leukemic mice.
  
  
  METHODS
  CD3AK cells in normal DBA/2 murine splenocytes were induced with anti-CD3 antibody and low dose recombinant interleukin-2 (rIL-2). The P 388 murine leukemia model was induced by i.p. injection of P 388 cells into normal DBA/2 mice. The tumor-bearing mice were administrated with adoptively transferred CD3AK Cells and/or CTX and/or KSC.
  
  
  RESULTS
  After tumor inoculation, the cellular immune function of P 388-bearing mice was supressed markedly. Adoptive transfer of CD3AK cells with low dose rIL-2 into the P 388 mice significantly enhanced the splenocyte proliferation (SP) induced by Con A, the NK cell activity and the splenocytic IL-2 production and prolonged their survival (45.19%); CTX (200 mg/kg) alone prolonged the survival of P 388-bearing mice (29.90%), but further decreased the immunodeficiency; combination of CTX and CD3AK passive transfer could prevent the reduction of SP, NK activity and IL-2 production in the leukemic mice and prolonged the survival (59.45%), combination of KSC and adoptively transfected CD2AK cells and/or CTX had a much better therapeutic efficacy for P 388 murine leukemia, 12.50%-75.00% of the leukemic mice were cured.
  
  
  CONCLUSIONS
  KSC is a hopeful biological response modifier in cancer biotherapy, and tumor killing effector cells and chemotherapy plus BRM might be a promising candidate for human leukemia biotherapy.
authors.affiliation: Lanzhou Medical College, Langzhou 730000.
authors.forename: H
authors.initials: H
authors.lastname: Wei
authors.forename: L
authors.initials: L
authors.lastname: Ma
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D017252:CD3 Complex / Q000378:metabolism*; D002351:Carrageenan / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000627:therapeutic use*; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000276:immunology; D007941:Leukemia P388 / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D008297:Male; D051379:Mice; D016566:Organoselenium Compounds / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017252:CD3 Complex; D007376:Interleukin-2; D016566:Organoselenium Compounds; C079969:kappa-selenocarrageenan; D003520:Cyclophosphamide; D002351:Carrageenan